We reported previously a HLA-A24-restricted antigenic peptide, survivin-2B80-88 (AYACNTSTL), recognized by CD8 + CTL. This peptide was derived from survivin protein, an inhibitor of apoptosis proteins, expressed in a variety of tumors, such as adenocarcinoma, squamous cell carcinoma, and malignant melanoma. In this report, we provide further evidence that survivin-2B80-88 peptide might serve as a potent immunogenic cancer vaccine for various cancer patients. Overexpression of survivin was detected in surgically resected primary tumor specimens of most breast and colorectal cancers and some gastric cancers as assessed by immunohistochemical study. HLA-A24/survivin-2B80-88 tetramer analysis revealed that there existed an increased number of CTL precursors in peripheral blood mononuclear cells (PBMC) of HLA-A24 + cancer patients, and in vitro stimulation of PBMCs from six breast cancer patients with survivin-2B80-88 peptide could lead to increases of the CTL precursor frequency. Furthermore, CTLs specific for this peptide were successfully induced from PBMCs in all 7 (100%) patients with breast cancers, 6 of 7 (83%) patients with colorectal cancers, and 4 of 7 (57%) patients with gastric cancers. These data indicate that survivin expressed in tumor tissues is antigenic in cancer patients, and survivin-2B80-88-specific CTLs are present in PBMCs of various cancer patients. Our study raises the possibility that this peptide may be applicable as a general cancer vaccine to a large proportion of HLA-A24 + cancer patients.
INTRODUCTION
In the past decade, many tumor-associated antigens, which can be recognized by CTLs, have been identified (1 -4) . However, such tumor-associated antigens have been expressed in certain limited tumor cells, such as melanomas. Therefore, the identification of widely expressed tumor-associated antigens is urgently required for the development of cancer immunotherapy in more common malignancies of epithelial origins like adenocarcinoma and squamous cell carcinomas.
Survivin was initially isolated as one of the inhibitors of the apoptosis protein family with only one baculovirus inhibitors of apostosis protein (IAP) repeat domain (5) . Following the first report, survivin has been proven to be one of the chromosome passenger proteins and to play an important role in mitosis and spindle checkpoint (6 -8) . Survivin is aberrantly expressed in various kinds of cancer cells but is undetectable in normal differentiated adult tissues, with the exception of testis, thymus, and placenta. Indeed, the accumulated reports of survivin expression in human malignant tumor tissues over the past several years are consistent with the observation that the expression of survivin was enhanced in various human cancers in comparison with adjacent normal tissues, including nonHodgkin's lymphoma (5) and many other malignancies (9 -27) . Moreover, several reports suggest that overexpression of survivin in cancer cells is associated with unfavorable clinicopathologic variables, such as poor prognosis and shorter patient survival rates.
Thus, with its high expression profile in cancer cells and function of protecting cancer cells from apoptotic stimuli, survivin is thought to be one of the most ideal immunologic target molecules for cancer treatment. With this mind, we attempted to establish an immunotherapy based on targeting the survivin molecule. In our previous report, we provided data showing that the survivin-2B80-88 peptide can be presented by HLA-A24 and that CTLs induced with this peptide could recognize survivin-positive HLA-A24 + cancer cells (28) . In this report to further investigate its applicability to tumor immunotherapy, we confirmed survivin expression in a greater number of breast, colorectal, and gastric cancer specimens. Furthermore, it was possible to induce survivin peptide -specific CTLs from most of these patients' peripheral blood mononuclear cells (PBMC). These data strongly suggest that the survivin-2B80-88 peptide is one of ideal general cancer vaccines for immunotherapy of HLA-A24 + patients.
MATERIALS AND METHODS
Patients and Samples. The surgically resected specimens used in this study were obtained from HLA-A24 + patients with breast, colorectal, and gastric cancers who underwent potentially curative resection at the Department of Surgery, Sapporo Medical University Hospital and its affiliated hospitals. Peripheral blood was obtained from patients after obtaining their informed consent.
Immunohistochemical Staining of Survivin, Cell Lines, and Culture Media. For immunohistochemical detection of survivin protein, the standard avidin-biotin-peroxidase complex technique was done with simple stain MAX-PO (MULTI) methods (Nichirei, Tokyo, Japan).
K562 cells were purchased from American Type Culture Collection (Manassas, VA). Lymphoblastoid cell lines transfected with HLA-A*2402 (C1R-A*2402) and HLA-A*31012 (C1R-A*31012) were kind gifts from Dr. M. Takiguchi (Kumamoto University School of Medicine, Kumamoto, Japan). Cells were cultured in RPMI 1640 supplemented with 2 mmol/L L-glutamine, 10% FCS, 100 units/mL penicillin G, and 100 Ag/mL streptomycin and were maintained at 37jC in a humidified 5% CO 2 atmosphere. Hygromycin B (0.5 mg/mL, WAKO Chemicals, Osaka, Japan) was continuously added to the culture medium for C1R-A*2402 and C1R-A*31012 cells.
Peptides and Cytokines. We used a HLA-A24-restricted survivin-derived antigenic peptide (AYACNTSTL), designated as 2B80-88 peptide, and a HLA-A24-restricted SYT-SSX SS393 peptide (GYDQIMPKK) that was derived from (X;18) chromosomal translocation in synovial sarcomas (29) . Peptides were kindly provided by Sumitomo Pharmaceutical (Osaka, Japan). They were resolved in DMSO at the concentration of 5 mg/mL and stored at À80jC. Human recombinant interleukin (IL)-2 and IL-4 were a kind gifts from Takeda Pharmaceutical Co. (Osaka, Japan) and Ono Pharmaceutical Co. (Osaka, Japan), respectively. Human recombinant granulocyte-macrophage colony-stimulating factor was a kind gift from Kirin (Tokyo, Japan) and Novartis Pharmaceutical (Basel, Switzerland). Human recombinant IL-7 was purchased from Invitrogen (San Diego, CA).
Fluorescence-Activated Cell Sorting Analysis and Tetramer Construction. Fluorescence-activated cell sorting analysis was done for the expression of HLA-A24 and peptide-specific tetramer analysis. To detect the cell surface expression of HLA-A24 molecule, after washing with PBS, the cells were incubated with anti-HLA-A24 antibody (c7709A2.6, a kind gift from Dr. P.G. Coulie, Brussels, Belgium; ref. 30) for 1 hour at 4jC. After washing with PBS, the cells were incubated with diluted FITC-labeled goat anti-mouse IgG + IgM antibody (KPL, Guildford, United Kingdom) and, after washing again with PBS, were fixed with formaldehyde and analyzed with FACScan (BD Biosciences, Mountain View, CA) and CellQuest software (BD Biosciences).
HLA-A24/peptide tetramers were constructed according the procedure described by Altman et al. (31) . A soluble form of mutated HLA-A24 heavy chain (32) and human h 2 -microgloblin were refolded with the synthesized survivin-2B80-88 peptides as described previously (29) . Briefly, the refolded HLA-A24/peptide complexes were biotinylated by incubation for 17 hours at room temperature with BirA enzyme (Avidity, Denver, CO). The biotinylated product was purified using fast protein liquid chromatography. Tetrameric HLA-A24/ peptide complexes were produced by adding streptavidinphycoerythrin (Vector Laboratories, Burlingame, CA) to achieve a 1:4 molar ratio. For flow cytometric analysis, PBMCs were isolated from the blooded samples using Ficoll-Conray density gradient centrifugation and then were stained with the appropriate phycoerythrin-labeled tetramers at 37jC for 20 minutes and with FITC-conjugated anti-CD8 monoclonal antibody (BD Biosciences) at 4jC for 30 minutes. Cells were washed twice with PBS before fixation in 1% formaldehyde. Analysis of stained PBMCs was done using FACScan and CellQuest software. The frequency of CTL precursors (CTLp) was calculated as the number of tetramer-positive cells divided by the number of CD8 + cells. Peptide-Specific CTL Induction with Dendritic Cells and Phytohemagglutinin-Blasts. CTL induction method using autologous dendritic cells and PHA-blasts as antigenpresenting cells (APC) from cancer patients' PBMCs was done as described previously (28, 33) . PBMCs were isolated from cancer patients' blood with Lymphoprep (Nycomed, Oslo, Norway), cultured in AIM-V medium (Invitrogen Life Technologies, Carlsbad, CA) at 37jC for 1 hour, and separated into adherent cells and nonadherent cells. Autologous immature monocyte-derived dendritic cells were generated from plastic flask adherent cells by culturing in AIM-V medium supplemented with HEPES (10 mmol/L), 2-mercaptoethanol (50 Amol/L), granulocyte-macrophage colony-stimulating factor (1,000 units/mL), and IL-4 (1,000 units/mL) for 7 days. CD8 + cells were isolated from plastic flask nonadherent cells of PBMCs with magnetic affinity cell sorting separation system (Miltenyi Biotech, Bergisch Gladbach, Germany) using anti-CD8 monoclonal antibody coupled with magnetic microbeads according to manufacturer's instruction. PHA-blasts were derived from CD8
À cells by culturing in AIM-V supplemented with HEPES (10 mmol/L), 2-mercaptoethanol (50 Amol/L), IL-2 (100 units/mL), and PHA (1 Ag/mL) for 3 days followed by culture in AIM-V medium without PHA for 4 days. APCs (dendritic cells and PHA-blasts) were cultured in AIM-V medium supplemented with 50 Amol/L peptide at room temperature for 1 hour and washed with AIM-V thrice and then irradiated 100 Gy and used for stimulation of CTLs. CTL induction procedure was initiated by stimulating 2 Â 10 6 CD8 + cells with peptide-pulsed autologous dendritic cells at a 20:1 effector/APC ratio in AIM-V supplemented with HEPES, 2-mercaptoethanol, and IL-7 (10 ng/mL) for 7 days at 37jC. The following stimulation was done with peptide-pulsed PHA-blasts at a 5:1 effector/APC ratio. On the next day of the second stimulation, IL-2 was added to the culture at a concentration of 50 units/mL. The same CTL stimulation cycle with PHA-blasts was then done twice more over the period of 2 weeks. One week after the fourth stimulation, the cytotoxic activity of the CTLs was measured by 51 Cr release assay. Cytotoxicity Assay. The cytotoxic activities of CTLs were measured by 51 Cr release assay as described previously (34) . Briefly, target cells were labeled with 100 ACi 51 Cr for 1 hour at 37jC and washed with RPMI 1640 thrice. Then, 2 Â 10 3 51 Cr-labeled target cells were incubated with effector cells at various effector/target (E:T) ratios at 37jC for 6 hours in Vbottomed 96-well microtiter plates. Then, supernatants were collected and the radioactivity was measured with a gamma counter. % Specific lysis was calculated as % Specific lysis = (Experiment release À Spontaneous release) Â 100 / (Maximum release À Spontaneous release). For preparation of peptidepulsed target cells, C1R-*A2402 cells, C1R-*A31012, or PHAblast T cells were incubated with 1 Ag/mL peptide at room temperature for 1 hour before the assay. 
RESULTS
Survivin Expression Profiles in Breast, Colon, and Gastric Cancer Specimens. Several research groups have shown that the expression of survivin was up-regulated in various types of cancer specimens. In our current study, we focused on breast, colorectal, and gastric cancers because of higher incidence among malignancies in Japanese. Using reverse transcription-PCR method, we showed previously that the survivin mRNA level was elevated in several cancer cell lines, including adenocarcinoma cells, squamous cell carcinoma cells, renal cell carcinoma cells, and melanoma cells (28) . In this report, immunohistochemical staining was done to study the expression profiles of survivin protein in surgically resected primary tumor specimens.
Because survivin is suggested to be involved in the process of nuclear chromatin organization, we examined if survivin was detected in the nucleus. In concurrence with previous reports (9, 10, 16) , our data indicated that survivin was overexpressed in breast, colorectal, and gastric cancer tissues ( Fig. 1A-C ; Tables 1,  2 , and 3). Survivin overexpression was detected in all the cases of breast invasive ductal carcinomas (Table 1 ) and colon adenocarcinomas ( Table 2) . In gastric cancer, six of nine cases were survivin positive (Table 3) . It was noted that survivin was detected in the nucleus as well as in the cytoplasm in most of breast cancers ( Fig. 1A ; Table 1 ), whereas survivin was detected mainly in the nucleus of colon cancer tissues (Fig. 1B) and gastric cancer tissues (Tables 2 and 3) .
Immunogenicity and CTL Precursor Induction with Survivin-2B80-88 Peptide in Cancer Patients. Because the expression of survivin was up-regulated in most cases of breast, colorectal, and gastric cancers, we next determined whether this protein could be an antigenic target recognized by CTL. To confirm this point, we first studied the CTLp frequency in several survivin-positive cancer patients' PBMCs by using HLA-A24/survivin-2B80-88 peptide tetramer as described previously (31) . As shown in Table 4 , CTLp frequencies were >0.1% in 8 of 13 survivin-positive cancer patients, whereas they were <0.1% in 5 healthy individuals. There did not seem to be obvious correlation between survivin-2B80-88 peptide-specific CTLp frequency and clinical stages, but the data strongly implied that survivin protein overexpressed in cancer tissues might be antigenic and survivin-2B80-88 peptide could be recognized by T cells in the context of HLA-A*2402 molecule in these cancer patients.
Because survivin was frequently overexpressed in breast cancers, we next examined if stimulation of PBMCs in vitro with survivin-2B80-88 peptide was capable of increasing the Fig. 1 Immunohistochemical staining of survivin protein in surgically resected specimens. Expression of survivin protein in breast (A), colorectal (B), and gastric cancer (C) specimens was assessed by standard immunohistochemical staining method as described in Materials and Methods. Photographs in the lower column are magnified views of boxes in the upper column. Cr release assay.
frequency of peptide-specific CTL using breast cancer patients' PBMCs. The peptide-specific CTLs were induced by mixed lymphocyte peptide culture (MLPC) in the same manner as described in our previous reports (28) . CTL frequencies analyzed by HLA-A24/survivin-2B80-88 tetramer were compared between pre-MLPC and post-MLPC. Figure  2A shows a representative data of breast cancer patient 3.
In vitro stimulation of PBMCs with survivin-2B80-88 peptide-pulsed APCs increased the CTL frequency from 0.07% to 0.89%. We did the similar MLPC experiments using a total of six cases of breast cancer. As shown in Fig.  2B , MLPC with survivin-2B80-88 peptide could lead to increases in the frequency of the peptide-specific CTLs in most cases of breast cancer, although the efficiency was distinct in each case. HLA-A24-Restricted Survivin-2B80-88 PeptideSpecific Cytotoxicity in Cancer Patients. We evaluated the cytotoxic activity of CTLs that were induced with survivin-2B80-88 peptide from breast, colorectal, or gastric cancer patients. CTLs were induced from HLA-A24-positive cancer patients' PBMCs by MLPC using autologous monocyte-derived dendritic cells and PHA-blasts as APCs. Then, HLA-A24-restricted peptide-specific cytotoxic activity was assessed by 51 Cr release assay using survivin-2B80-88 peptide-pulsed or nonpulsed C1R-A*2402 cells as target cells. HLA-A24-restricted SYT-SSX SS393 peptide was used as a negative control peptide. This peptide was derived from (X;18) chromosomal translocation in synovial sarcomas as reported previously (29) . We also used negative control target cells (i.e., survivin-2B80-88 peptide-pulsed C1R-*A31012 cells and nonpulsed K562 cells). As shown representatively in Fig. 3 , stimulation of PBMCs from breast cancer patient 4 (Fig. 3A ) and patient 7 ( Fig. 3B ) with survivin-2B80-88 peptide resulted in the induction of CTLs that were preferentially cytotoxic against survivin-2B80-88 peptide-pulsed C1R-A*2402 cells. However, these CTLs were less cytotoxic to SYT-SSX peptidepulsed C1R-A*2402 or nonpulsed C1R-A*2402 cells, although they showed some extent of background killing activity against C1R-A*2402 cells. These CTLs did not exert cytotoxicity against survivin-2B80-88 peptide-pulsed C1R-A*31012 or K562 cells. These data indicated that CTLs induced by MLPC with survivin-2B80-88 peptide had HLA-A*2402-restricted peptide-specific cytotoxicity. To know whether survivin-2B80-88-specific CTLs could exert cytotoxicity against autologous activated T cells that expressed survivin, we tested the cytotoxicity of the CTL against autologous PHA-blast cells. CTLs were induced from PBMCs of gastric cancer patient 9. Peptide-pulsed or nonpulsed autologous activated T cells were resistant to the CTLs, whereas the peptide-pulsed C1R-A*2402 cells were killed (Fig. 3C) . Therefore, it is probable that normal activated lymphocytes might have a protective mechanism against the cytotoxicity of CTLs even if they express survivin.
Finally, we examined the cytotoxic activity of CTLs induced by survivin-2B80-88 peptide in various cancer patients. As shown in Fig. 4A , survivin-2B80-88 peptide-specific CTLs could be successfully induced from all seven cases of breast cancer patients (summarized in Table 1 ). In colorectal cancer patients, specific CTLs could be induced from six (patients 1-6) of seven cases ( Fig. 4B; Table 2 ). Meanwhile, although Cr release assay. In gastric cancer patients, however, only four (patient 1-3 and 9) of the seven cases showed survivin-2B80-88 peptidespecific CTL induction ( Fig. 4C; Table 3 ). Although the number of gastric cancer patients examined in this study was not enough to know the accurate immunogenic potential of this peptide or correlation with clinical variables, it should be noted that survivin-2B80-88 peptide-specific CTL was successfully induced in PBMCs from patients (1-3 and 9) with survivinpositive gastric tumors but not from patients (5 and 6) with survivin-negative gastric tumors (Table 3) .
Cytotoxicity of the Survivin-2B80-88 Peptide-Specific CTL against HLA-A2402-Positive Adenocarcinoma Cells. To confirm that CTLs induced with survivin-2B80-88 peptide can react with survivin-expressing cancer cells in the context of HLA-A*2402, we examined cytotoxic activity against lung adenocarcinoma LNY-1-A*2402 cells that express both endogenous survivin and gene-transfected HLA-A*2402. As shown in Fig. 5 , CTLs induced from PBMCs of HLA-A24-positive breast (Fig. 5A), colorectal (Fig. 5B), and gastric (Fig. 5C ) cancer patients by MLPC with survivin-2B80-88 peptide exerted significant cytotoxicity against LNY-1-A*2402 cells but not against LNY-1 lacking HLA-A24 expression or K562 cells. These data indicate that survivin-2B80-88 peptide-specific CTLs were capable of recognizing endogenously processed survivin peptide in a HLA-A24-restricted manner.
Taken together, it was strongly indicated that survivin protein expressed in cancer cells was antigenic in HLA-A2402-positive cancer patients, and survivin-2B80-88 peptide might be suitable for the general cancer vaccine.
DISCUSSION
Among various types of malignancy, the incidence of breast, colorectal, and gastric cancers are the most frequent in Japanese population. In this study, to assess the immunogenic potency of survivin protein in these cancer patients, its expression and the frequency of survivin-specific CTLs were examined using surgically resected specimens and PBMCs of the patients. Tables 1, 2 , and 3. Because survivin is considered to be a chromosomal passenger protein and to play an important role in the mitotic process, we studied the nuclear expression as well as cytoplasmic expression of this protein. Survivin expression was detected in the nucleus of many cases of breast, colorectal, and gastric cancers, and it was also detected in the cytoplasm in some of these cancer tissues. These results were consistent with previous reports (9, 10, 16 ). An earlier study also reported that survivin was a cell cycle -regulated protein with a robust expression in the G 2 -M phase (6) . Immunofluorescence and confocal microscopy techniques showed that survivin was associated with the microtubule organization center interphase, centrosomes, and mitotic spindles at metaphase and relocated to midbodies in later telophase (6, 35) . Mahotka et al. showed that survivin-y Ex3 splicing variant had a potential nuclear localization signal and was localized in the nucleus, whereas survivin and survivin-2B splicing products were in the cytoplasm (36) . Because there is no antibody available that can detect the splicing variants specifically, it is hard to detect the subcellular localization of the variants. Besides the subcellular localization, we have shown previously that the mRNA levels of three survivin isoforms are comparable among them in most tumor cells (28) . Therefore, immunohistologic survivin detection even in the nucleus or in the cytosol should indicate the comparable production of survivin-derived antigenic peptides in cancer cells.
In this report, we also showed elevation of CTLp frequencies in HLA-A24-positive cancer patients' PBMCs by using HLA-A24/survivin-2B80-88 peptide tetramer. CTLp could be expanded in vitro by MLPC and showed peptide-specific cytotoxicity. These CTLs were also cytotoxic against HLA-A24-positive and survivin-positive adenocarcinoma cell lines (Fig. 5) . These data strongly indicate that survivin is one of the immunogenic tumor antigens in HLA-A24-positive cancer patients. It is noteworthy that there was a clear correlation between the survivin expression detected by immunohistochemistry and the CTL induction capability. Immunohistochemical detection of survivin expression might become one of the predictive markers in the survivin targeting immunotherapy of cancer.
It is likely that survivin is expressed in some normal tissues like thymus, testis, and placenta. Testis and placenta are immunoprivileged organs and rarely disclose classic HLA class I molecules to the immune system. Therefore, CTLs cannot recognize HLA class I -restricted antigens expressed in testis or placenta. However, because survivin is expressed in normal activated lymphocytes or stem cells in bone marrow, it is anticipated that those normal cells might become targets of survivin-specific CTLs. In this study, we showed that survivin-2B80-88-specific CTLs could not kill autologous activated T cells either in the peptide-pulsed condition or in nonpulsed condition. Our data are consistent with previous reports showing that immunocompetent cells, including CD4 + T cells, B cells, natural killer cells, and dendritic cells, are resistant to CTL activity (37). Schmidt et al. showed that HLA-A2-restricted survivin peptide -specific CTLs could not recognize activated B cells, activated T cells, immature dendritic cells, or mature dendritic cells, which express survivin (38) . Meanwhile, granzyme B is one of the most potent cytotoxic enzymes that are released from CTLs and activate cell death program inside the target cells. The resistance mechanism of normal lymphocytes and dendritic cells against CTLs has been explained at least in part by the presence of a potent granzyme B inhibitor, proteinase inhibitor-9, in those cells (38) . These findings suggest that although survivin may be expressed in some sorts of normal tissues it does not become an obvious drawback in the survivin targeting cancer immunotherapy.
In addition to the antiapoptotic effect, survivin is involved in the tumor angiogenesis (39) . Pathologic angiogenesis is essential for tumor outgrowth in vivo, and various tumor cells were reported to express angiogenic factors like vascular endothelial growth factor, basic fibroblast growth factor, and transforming growth factor-h. Treatment with antiangiogenic reagents was effective in the suppression of tumor growth and metastasis (40) . O'Connor et al. showed that vascular endothelial growth factor, one of the angiogenic factors, could induce 16-fold up-regulation of survivin expression in vascular endothelial cells, leading to the resistance against proapoptotic stimuli. Hence, survivin targeting immunotherapy of cancer should be advantageous not only to the anti -cell survival effect but also to the antiangiogenesis effect.
In conclusion, we provided evidence that survivin was overexpressed in a large proportion of breast, colorectal, and gastric cancer tissues. Survivin-2B80-88-specific CTLs could be induced efficiently from PBMCs of HLA-A24-positive Fig. 4 Induction of HLA-A24-restricted CTL from PBMCs of HLA-A24 + breast, colorectal, and gastric cancer patients. CTLs were induced from PBMCs of HLA-A24-positive breast (A), colorectal (B ), and gastric (C) cancer patients by MLPC with survivin-2B80-88 peptide as described in Materials and Methods. Cytotoxic activity of the CTL against survivin-2B80-88 peptide-pulsed C1R-A*2402 cells or C1R-A*31012 cells and nonpulsed K562 cells was analyzed by 51 Cr release assay at various E:T ratios.
survivin-positive cancer patients. Our overall data indicate that survivin targeting immunotherapy with survivin-2B80-88 peptide should be suitable for HLA-A24 + breast, colorectal, or gastric cancer. Currently, a phase I clinical trial of survivin-2B80-88 peptide vaccine immunotherapy has been undertaken (41) . 
